ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Overcoming PEG Antigenicity: Statistical PEG Isomers Reduce Antibody Binding.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoscopic Characterization of the Thermal Phase Behavior of Random Poly(ethylene glycol-glycidyl methyl ether) Copolymers (rPEGs).Macromolecules · 2026Article
- Lipids and lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA delivery.Chemical science · 2026Article
- A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform.Macromolecular rapid communications · 2026Article
- Overcoming PEG Antigenicity: Statistical PEG Isomers Reduce Antibody Binding.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Poly(ethylene glycol) (PEG) is widely used in bioconjugation and nanomedicine due to its advantageous properties including solubility, biocompatibility, and pharmacokinetic benefits. However, PEG exposure can elicit anti-PEG antibodies (APAs), resulting in accelerated blood clearance and immune responses. To address this, "randomized PEG" (rPEG) is synthesized by incorporating the comonomer glycidyl methyl ether into PEG via anionic ring-opening polymerization. This structural isomer introduces "synthetic point mutations", impeding APA recognition. The interaction between rPEGs and APAs is systematically investigated in buffer solution using microscale thermophoresis and fluorescence correlation spectroscopy. Increasing comonomer content drastically reduced antibody binding, with rPEGs containing 52 mol% comonomer effectively preventing APA interaction. Monte Carlo simulations confirmed a reduction in consecutive ethylene glycol sequences to less than 16 units crucial for APA recognition. These results establish rPEG as a promising PEG alternative, mitigating immune recognition while retaining key properties. This is of key relevance for next-generation stealth polymers with improved biocompatibility for biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.